Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Siwen Hu

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Nature Cancer|August 9, 2021
PAK4 inhibition improves PD-1 blockade immunotherapyGabriel Abril-Rodriguez, Davis Y Torrejon, Wei Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2022
A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 ResistanceTimothy A Yap, Patricia M LoRusso, Deborah J Wong, et al.
Nature|January 11, 2018
High response rate to PD-1 blockade in desmoplastic melanomasZeynep Eroglu, Jesse M Zaretsky, Siwen Hu-Lieskovan, et al.
Biorxiv : the Preprint Server for Biology|December 25, 2025
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated MelanomaMona Foth, Wontak Kim, Kayla T O'Toole, et al.
Cancer Discovery|December 2, 2016
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 MutationsDaniel Sanghoon Shin, Jesse M Zaretsky, Helena Escuin-Ordinas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2023
The New NCI Precision Medicine TrialsLyndsay N Harris, Charles D Blanke, Harry P Erba, et al.
Cancer Research|May 22, 2026
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated MelanomaMona Foth, Wontak Kim, Kayla O'Toole, et al.
The New England Journal of Medicine|July 20, 2016
Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaJesse M Zaretsky, Angel Garcia-Diaz, Daniel S Shin, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2024
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapyRachel Woodford, Janet McKeown, Lotte L Hoeijmakers, et al.
Nature Medicine|August 17, 2023
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trialAri VanderWalde, Shay L Bellasea, Kari L Kendra, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Nature Cancer|August 9, 2021
PAK4 inhibition improves PD-1 blockade immunotherapyGabriel Abril-Rodriguez, Davis Y Torrejon, Wei Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2022
A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 ResistanceTimothy A Yap, Patricia M LoRusso, Deborah J Wong, et al.
Nature|January 11, 2018
High response rate to PD-1 blockade in desmoplastic melanomasZeynep Eroglu, Jesse M Zaretsky, Siwen Hu-Lieskovan, et al.
Biorxiv : the Preprint Server for Biology|December 25, 2025
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated MelanomaMona Foth, Wontak Kim, Kayla T O'Toole, et al.
Cancer Discovery|December 2, 2016
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 MutationsDaniel Sanghoon Shin, Jesse M Zaretsky, Helena Escuin-Ordinas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2023
The New NCI Precision Medicine TrialsLyndsay N Harris, Charles D Blanke, Harry P Erba, et al.
Cancer Research|May 22, 2026
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated MelanomaMona Foth, Wontak Kim, Kayla O'Toole, et al.
The New England Journal of Medicine|July 20, 2016
Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaJesse M Zaretsky, Angel Garcia-Diaz, Daniel S Shin, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2024
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapyRachel Woodford, Janet McKeown, Lotte L Hoeijmakers, et al.
Nature Medicine|August 17, 2023
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trialAri VanderWalde, Shay L Bellasea, Kari L Kendra, et al.
Pageof 10